This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mincey, B. A. Articles by Perez, E. A. Search for Related Content PubMed PubMed Citation Articles by Mincey, B. A. Articles by Perez, E. A.

Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials

^a Division of General Internal Medicine, ^b Multidisciplinary Breast Clinic, ^c Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA

Correspondence: Edith A. Perez, M.D., Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32224, USA. Telephone: 904-953-7283; Fax: 904-953-2315; e-mail: perez.edith{at}mayo.edu

Determining the optimal individual adjuvant systemic therapy for breast cancer patients is a challenging undertaking because it requires translating data from clinical trials that have involved thousands of patients into a highly individualized, risk-adjusted approach for the patient at hand. Choosing adjuvant therapy for women with breast cancer includes consideration of four issues: A) evaluation of risk of relapse; B) extrapolation of results from clinical trials; C) therapeutic ratio, and D) the patient's preferences following a thorough discussion with her physician. Data from recently completed phase III adjuvant trials and worldwide consensus conferences document the benefits of adjuvant therapy in improving disease-free survival and overall survival for patients diagnosed with invasive breast cancer >1.0 cm in size. The benefits of hormonal therapy are clear, but limited to patients with estrogen receptor-positive breast cancer. Anthracyclines lead to improved outcomes compared with nonanthracycline regimens. Taxanes appear to improve disease-free survival in patients with node-positive disease, although longer follow-up is required to assess their impact on overall survival. Some countries have reported a reduction in the mortality rate from breast cancer over the past several years. The improved survival rate is due, at least in part, to the use of adjuvant systemic therapy. Ongoing studies are evaluating targeted therapies, with the potential of remarkably improving patient outcome.

Key Words. Adjuvant therapy • Breast cancer • Taxanes • Anthracyclines

This article has been cited by other articles:

				D. Li, Y. Li, X. Wu, Q. Li, J. Yu, J. Gen, and X.-L. Zhang Knockdown of Mgat5 Inhibits Breast Cancer Cell Growth with Activation of CD4+ T Cells and Macrophages J. Immunol., March 1, 2008; 180(5): 3158 - 3165. [Abstract] [Full Text] [PDF]

				R. Oratz, D. Paul, A. L. Cohn, and S. M. Sedlacek Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer J. Oncol. Pract, July 1, 2007; 3(4): 182 - 186. [Abstract] [Full Text] [PDF]

				B. Z. Ring, R. S. Seitz, R. Beck, W. J. Shasteen, S. M. Tarr, M. C.U. Cheang, B. J. Yoder, G. T. Budd, T. O. Nielsen, D. G. Hicks, et al. Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., July 1, 2006; 24(19): 3039 - 3047. [Abstract] [Full Text] [PDF]

				E. Espinosa, J.A. F. Vara, A. Redondo, J.J. Sanchez, D. Hardisson, P. Zamora, F. G. Pastrana, P. Cejas, B. Martinez, A. Suarez, et al. Breast Cancer Prognosis Determined by Gene Expression Profiling: A Quantitative Reverse Transcriptase Polymerase Chain Reaction Study J. Clin. Oncol., October 10, 2005; 23(29): 7278 - 7285. [Abstract] [Full Text] [PDF]

				S. Madhusudan, M. Foster, S. R. Muthuramalingam, J. P. Braybrooke, S. Wilner, K. Kaur, C. Han, S. Hoare, F. Balkwill, D. C. Talbot, et al. A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor {alpha} Inhibitor in Patients with Metastatic Breast Cancer Clin. Cancer Res., October 1, 2004; 10(19): 6528 - 6534. [Abstract] [Full Text] [PDF]